無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

大うつ病性障害(MDD) - 市場の洞察、疫学、市場予測 〜2027年

Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027

発行 DelveInsight Business Research LLP 商品コード 602082
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
大うつ病性障害(MDD) - 市場の洞察、疫学、市場予測 〜2027年 Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027
出版日: 2018年12月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の大うつ病性障害(MDD)市場について調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、主要7カ国の市場動向、疫学的予測、アンメットニーズ、治療薬別の市場規模の推移の予測、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 レポート概要

第2章 大うつ病性障害(MDD)市場の概要

  • 市場規模(実績値)
  • 市場規模(予測値)

第3章 疾患の背景と概要:大うつ病性障害(MDD)

  • イントロダクション
  • 原因
  • 病態生理
  • 症状
  • リスク因子
  • 診断

第4章 疫学と患者人口

  • 主要7カ国の有病数
  • 主要7カ国の有病数:性別(実数・予測値)
  • 主要7カ国の診断数と治療可能な症例数(実数・予測値)

第5章 疾患の疫学:国別

  • 米国
    • 有病数
    • 有病数:性別(実数・予測値)
    • 診断数と治療可能な症例数(実数・予測値)
  • EU5カ国
    • ドイツ
      • 有病数
      • 有病数:性別(実数・予測値)
      • 診断数と治療可能な症例数(実数・予測値)
    • フランス
      • 有病数
      • 有病数:性別(実数・予測値)
      • 診断数と治療可能な症例数(実数・予測値)
    • イタリア
      • 有病数
      • 有病数:性別(実数・予測値)
      • 診断数と治療可能な症例数(実数・予測値)
    • スペイン
      • 有病数
      • 有病数:性別(実数・予測値)
      • 診断数と治療可能な症例数(実数・予測値)
    • 英国
      • 有病数
      • 有病数:性別(実数・予測値)
      • 診断数と治療可能な症例数(実数・予測値)
  • 日本
    • 有病数
    • 有病数:性別(実数・予測値)
    • 診断数と治療可能な症例数(実数・予測値)

第6章 治療行為

  • 治療アルゴリズム
  • 治療ガイドライン

第7章 上市済み医薬品

  • アリピプラゾール:BristolMyers Squibb
    • 製品説明
    • 作用機序
    • 規制のマイルストーン
    • 長所と短所
    • 安全性と有効性
    • 製品プロファイル
  • アプレンチン:Valeant Pharmaceuticals

第8章 新薬

  • キークロスコンテスト
  • Travivo:Fabre-Kramer Pharmaceuticals
    • 規制のマイルストーン
    • 臨床開発
    • 製品プロファイル
    • 臨床パイプライン活動
  • SAGE-217:Sage Therapeutics

第9章 大うつ病性障害(MDD)市場規模

  • 主な所見
  • 主要7カ国の市場分析
    • 市場概要
    • 市場規模の推移と予測:地域別

第10章 主要7カ国の分析:国別

  • 米国
    • 市場規模
    • 市場規模:治療薬別
  • ドイツ
    • 市場規模
    • 市場規模:治療薬別
  • フランス
    • 市場規模
    • 市場規模:治療薬別
  • 英国
    • 市場規模
    • 市場規模:治療薬別
  • スペイン
    • 市場規模
    • 市場規模:治療薬別
  • イタリア
    • 市場規模
    • 市場規模:治療薬別
  • 日本
    • 市場規模
    • 市場規模:治療薬別

第11章 市場の成長要因

第12章 市場の障壁

第13章 調査方法

  • 参考資料のリスト

第14章 DelveInsightのサービス内容

第15章 免責事項

第16章 DelveInsightについて

図表

List of Tables

  • Table 1: Prevalent Cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Table 2: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Table 3: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Table 4: Prevalent Cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Table 5: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Table 6: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Table 7: Prevalent Cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Table 8: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Table 9: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Table 10: Prevalent Cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Table 11: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Table 12: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Table 13: Prevalent Cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Table 14: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Table 15: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Table 16: Prevalent Cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Table 17: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Table 18: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Table 19: Prevalent Cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Table 20: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Table 21: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Table 22: Prevalent Cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Table 23: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Table 24: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Table 25: Travivo, Clinical Trials by Recruitment status, 2018
  • Table 26: Travivo, Clinical Trials by Zone, 2018
  • Table 27: SAGE-217, Clinical Trials by Recruitment status, 2018
  • Table 28: SAGE-217, Clinical Trials by Zone, 2018
  • Table 29: Total 7 Major Market Size in USD, Million (2016-2027)
  • Table 30: Region wise Market Size) in USD, Million (2016-2027)
  • Table 31: 7MM-Market Size by Therapy in USD, Million (2016-2027)
  • Table 32: United States Market Size in USD, Million (2016-2027)
  • Table 33: United States Market Size by Therapy in USD, Million (2016-2027)
  • Table 34: Germany Market Size in USD, Million (2016-2027)
  • Table 35: Germany Market Size by Therapy in USD, Million (2016-2027)
  • Table 36: France Market Size in USD, Million (2016-2027)
  • Table 37: France Market Size by Therapy in USD, Million (2016-2027)
  • Table 38: United Kingdom Market Size in USD, Million (2016-2027)
  • Table 39: United Kingdom Market Size by Therapy in USD, Million (2016-2027)
  • Table 40: Spain Market Size in USD, Million (2016-2027)
  • Table 41: Spain Market Size by Therapy in USD, Million (2016-2027)
  • Table 42: Italy Market Size in USD, Million (2016-2027)
  • Table 43: Italy Market Size by Therapy in USD, Million (2016-2027)
  • Table 44: Japan Market Size in USD, Million (2016-2027)
  • Table 45: Japan Market Size by Therapy in USD, Million (2016-2027)

List of Figures

  • Figure 1: Prevalent Cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Figure 2: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Figure 3: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in 7MM (2016-2027)
  • Figure 4: Prevalent Cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Figure 5: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Figure 6: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the US (2016-2027)
  • Figure 7: Prevalent Cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Figure 8: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Figure 9: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Germany (2016-2027)
  • Figure 10: Prevalent Cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Figure 11: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Figure 12: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Italy (2016-2027)
  • Figure 13: Prevalent Cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Figure 14: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Figure 15: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Spain (2016-2027)
  • Figure 16: Prevalent Cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Figure 17: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Figure 18: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the France (2016-2027)
  • Figure 19: Prevalent Cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Figure 20: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Figure 21: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the UK (2016-2027)
  • Figure 22: Prevalent Cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Figure 23: Gender specific Prevalent cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Figure 24: Diagnosed and treatable cases of Major Depressive Disorder (MDD) in the Japan (2016-2027)
  • Figure 25: Travivo, Clinical Trials by Recruitment status, 2018
  • Figure 26: Travivo, Clinical Trials by Zone, 2018
  • Figure 27: SAGE-217, Clinical Trials by Recruitment status, 2018
  • Figure 28: SAGE-217, Clinical Trials by Zone, 2018
  • Figure 29: Total 7 Major Market Size in USD, Million (2016-2027)
  • Figure 30: Region wise Market Size) in USD, Million (2016-2027)
  • Figure 31: 7MM-Market Size by Therapy in USD, Million (2016-2027)
  • Figure 32: United States Market Size in USD, Million (2016-2027)
  • Figure 33: United States Market Size by Therapy in USD, Million (2016-2027)
  • Figure 34: Germany Market Size in USD, Million (2016-2027)
  • Figure 35: Germany Market Size by Therapy in USD, Million (2016-2027)
  • Figure 36: France Market Size in USD, Million (2016-2027)
  • Figure 37: France Market Size by Therapy in USD, Million (2016-2027)
  • Figure 38: United Kingdom Market Size in USD, Million (2016-2027)
  • Figure 39: United Kingdom Market Size by Therapy in USD, Million (2016-2027)
  • Figure 40: Spain Market Size in USD, Million (2016-2027)
  • Figure 41: Spain Market Size by Therapy in USD, Million (2016-2027)
  • Figure 42: Italy Market Size in USD, Million (2016-2027)
  • Figure 43: Italy Market Size by Therapy in USD, Million (2016-2027)
  • Figure 44: Japan Market Size in USD, Million (2016-2027)
  • Figure 45: Japan Market Size by Therapy in USD, Million (2016-2027)
目次
Product Code: DIMI0314

DelveInsight's ‘Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Major Depressive Disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Major Depressive Disorder (MDD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Major Depressive Disorder (MDD) - Disease Understanding and Treatment Algorithm

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called Major Depressive Disorder or clinical depression, it affects how patient feel, think and behave and can lead to a variety of emotional and physical problems.

The exact cause of Major Depressive Disorder (MDD) isn't known. However, there are several factors that can increase the risk of developing the condition. A combination of genes and stress can affect brain chemistry and reduce the ability to maintain mood stability. Changes in the balance of hormones might also contribute to the development of Major Depressive Disorder (MDD).

Symptoms of Major Depressive Disorder (MDD) may include-Feelings of sadness, tearfulness, hopelessness, Sleep disturbances, including insomnia or sleeping too much, Anxiety, agitation or restlessness etc.

The DelveInsight Major Depressive Disorder (MDD) market report gives the thorough understanding of the Major Depressive Disorder (MDD) by including details such as disease definition, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Major Depressive Disorder (MDD) in the US, Europe, and Japan.

Major Depressive Disorder (MDD) Epidemiology

The Major Depressive Disorder (MDD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalent population of Major Depressive Disorder (MDD), Gender specific Prevalent of Major Depressive Disorder (MDD), Diagnosed and treatable Cases of Major Depressive Disorder (MDD)] scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per Anxiety and Depression Association of America (ADAA), the leading cause of MDD disability in the U.S. for ages 15 to 44.3.MDD affects about 6.7%of the U.S. population age 18 and older in a given year. While Major Depressive Disorder can develop at any age, the median age at onset is 32.5 years old. More prevalent in women than in men.

According to National Institute of Mental Health (NIMH), the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%). Major depression is one of the most common mental disorders in the United Stat. In 2016, an estimated 10.3 million U.S. adults aged 18 or older had at least one major depressive episode with severe impairment. This number represented 4.3% of all U.S. adults. The prevalence of major depressive episode was higher among adult females (8.5%) compared to males (4.8%). The prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%).

DelveInsight estimates that the prevalent population of Major Depressive Disorder (MDD) will significantly change during the study period [2016-2027].

Major Depressive Disorder (MDD) Drug Chapters

This segment of the Major Depressive Disorder (MDD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently treatment of Major Depressive Disorder (MDD) include -Antidepressant medications (Selective serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants and atypical antidepressants).

Additionally, there are some FDA approved therapies for the treatment of Major Depressive Disorder (MDD) which include-Aripiprazole (BristolMyers Squibb), Aplenzin (Valeant Pharmaceuticals), Emsam (Somerset pharmaceuticals)

Key players such as Fabre-Kramer Pharmaceuticals, Sage Therapeutics and many others are involved in developing therapies for Major Depressive Disorder (MDD). Expected launch of emerging therapies such as Travivo (Fabre-Kramer Pharmaceuticals), SAGE-217 (Sage Therapeutics) and some other are expected to change the treatment landscape of Major Depressive Disorder (MDD) in upcoming years.

Major Depressive Disorder (MDD) Market Outlook

The Major Depressive Disorder (MDD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Major Depressive Disorder (MDD) in 7MM is expected to increase from 2016-2027.

Major Depressive Disorder (MDD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Major Depressive Disorder (MDD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Major Depressive Disorder (MDD) Report Key Strengths

  • 10 Years Forecast
  • 7MMCoverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Major Depressive Disorder (MDD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Table of Contents

1. Report Introduction

2. Major Depressive Disorder (MDD) Market Overview at a Glance

  • 2.1. 7 Major Market Size of Major Depressive Disorder (MDD) in 2017
  • 2.2. 7 Major Market Size of Major Depressive Disorder (MDD) in 2027

3. Disease Background and Overview: Major Depressive Disorder (MDD)

  • 3.1. Introduction
  • 3.2. Causes
  • 3.3. Pathophysiology
  • 3.4. Symptoms
  • 3.5. Risk Factor
  • 3.6. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. 7MM Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
  • 4.2. 7MM Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
  • 4.3. 7MM Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)

5. Major Depressive Disorder (MDD): Country- Wise Epidemiology

  • 5.1. United States
  • 5.2. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
  • 5.3. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
  • 5.4. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
  • 5.5. EU-5
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Germany
      • 5.5.2.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.2.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.2.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.5.3. France
      • 5.5.3.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.3.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.3.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.5.4. Italy
      • 5.5.4.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.4.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.4.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.5.5. Spain
      • 5.5.5.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.5.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.5.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.5.6. United Kingdom
      • 5.5.6.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.6.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
      • 5.5.6.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
  • 5.6. Japan
    • 5.6.1. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.6.2. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
    • 5.6.3. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)

6. Treatments & Medical Practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Marketed drug

  • 7.1. Aripiprazole: BristolMyers Squibb
    • 7.1.1. Product description
    • 7.1.2. Mechanism of Action
    • 7.1.3. Regulatory Milestones
    • 7.1.4. Advantages & Disadvantages
    • 7.1.5. Safety and Efficacy
    • 7.1.6. Product Profile
  • 7.2. Aplenzin: Valeant Pharmaceuticals
    • 7.2.1. Product description
    • 7.2.2. Mechanism of Action
    • 7.2.3. Regulatory Milestones
    • 7.2.4. Advantages & Disadvantages
    • 7.2.5. Safety and Efficacy
    • 7.2.6. Product Profile

To be continued in the report…

8. Emerging Therapies

  • 8.1. Key Cross Competition
  • 8.2. Travivo: Fabre-Kramer Pharmaceuticals
    • 8.2.1. Regulatory Milestones
    • 8.2.2. Clinical Development
    • 8.2.3. Product Profile
    • 8.2.4. Clinical Pipeline Activity
      • 8.2.4.1. Ongoing Trials Information
      • 8.2.4.2. Clinical Trial by Phase
  • 8.3. SAGE-217: Sage Therapeutics
    • 8.3.1. Regulatory Milestones
    • 8.3.2. Clinical Development
    • 8.3.3. Product Profile
    • 8.3.4. Clinical Pipeline Activity
      • 8.3.4.1. Ongoing Trials Information
      • 8.3.4.2. Clinical Trial by Phase

To be continued in report…

9. Major Depressive Disorder (MDD) Market Size

  • 9.1. Key Findings
  • 9.2. Total 7MM Major Depressive Disorder (MDD) Market Analysis
    • 9.2.1. Overview of Total Major Depressive Disorder (MDD)Market
    • 9.2.2. Market size of Major Depressive Disorder (MDD)Market by 7MM (2016-2027)

10. 7MM: Country-Wise Market Analysis

  • 10.1. United States Market Size
    • 10.1.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.1.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.2. Germany Market Size
    • 10.2.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.2.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.3. France Market Size
    • 10.3.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.3.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.4. United Kingdom Market Size
    • 10.4.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.4.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.5. Spain Market Size
    • 10.5.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.5.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.6. Italy Market Size
    • 10.6.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.6.2. Market Size of Major Depressive Disorder (MDD)by Therapies
  • 10.7. Japan Market Size
    • 10.7.1. Total Market Size of Major Depressive Disorder (MDD)
    • 10.7.2. Market Size of Major Depressive Disorder (MDD)by Therapies

11. Market Drivers

12. Market Barriers

13. Report Methodology

  • 13.1. Sources Used

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

Back to Top